Larimar Therapeutics (LRMR) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2026)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 15.61% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.73% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 14.05% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 11.65% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 411.50% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -3.34% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.66% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -3.26% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 19.96% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | -1.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.91% |
| Dec 31, 2025 | -9.20% |
| Sep 30, 2025 | -7.95% |
| Jun 30, 2025 | -6.85% |
| Mar 31, 2025 | -7.12% |
| Dec 31, 2024 | -5.65% |
| Sep 30, 2024 | -11.79% |
| Jun 30, 2024 | -11.34% |
| Mar 31, 2024 | -20.70% |
| Dec 31, 2023 | -13.04% |
| Sep 30, 2023 | -1.56% |
| Jun 30, 2023 | 0.10% |
| Mar 31, 2023 | 0.45% |
| Dec 31, 2022 | 44.75% |
| Sep 30, 2022 | -0.15% |
| Jun 30, 2022 | 0.62% |
| Mar 31, 2022 | 46.84% |
| Dec 31, 2021 | 40.90% |
| Sep 30, 2021 | 39.40% |
| Jun 30, 2021 | 36.90% |